基于慢性乙型肝炎合并代谢相关脂肪性肝病非靶向代谢谱的胆汁酸代谢分析OA

Objective:To analyze the differences in relative levels of bile acids in serum metabolomics of patients with chronic hepatitis B(CHB)complicated with metabolic dysfunction-associated fatty liver disease(MAFLD)Methods:From November 2020 to July 2021,28 patients with CHB 16 healthy controls,25 patients with MAFLD and 42 patients with CHB combined with MAFLD were selected from the Department of Infection,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology without antiviral treatment Patients were divided into four groups:MAFLD group,healthy control group(HC group)and CHB combined with MAFLD group(CHB+MAFLD group).General clinical data and serum samples were collected from the four groups of subjects,and non-targeted metabolomics analysis was performed on the serum using liquid chromatography-mass spectrometry(LC-MS)technology to screen for differential metabolites.The characteristics of liver inflammation and fibrosis in patients were analyzed from the perspective of bile acids.Results:The changes in bile acid composition vary among different disease groups.There are five different bile acids in the four groups,namely deoxycholic acid(DCA),glycocholic acid(GCA),glycodeoxycholic acid(GCDCA),taurocholic acid(TCA),and chenodeoxycholic acid(CDCA);The CHB+MAFLD group showed a significant increase in the relative level of CDCA compared to the CHB group,MAFLD group,and HC group.Conclusion:There is a significant difference in the relative levels of serum CDCA between CHB+MAFLD patients and healthy volunteers,patients with CHB,MAFLD.CDCA may serve as a potential biomarker for liver fibrosis in patients with CHB combined with MAFLD.